Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Larkins RG;Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
  • Source:
    Diabetes research and clinical practice [Diabetes Res Clin Pract] 1988 Jan 07; Vol. 4 (2), pp. 81-7.
  • Publication Type:
    Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print Cited Medium: Print ISSN: 0168-8227 (Print) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE
    • Publication Information:
      Publication: 1993- : Limerick : Elsevier Scientific Publishers
      Original Publication: Amsterdam : Elsevier Science Publishers B.V., c1985-
    • Subject Terms:
      Diabetes Mellitus, Type 1/*blood ; Diabetes Mellitus, Type 2/*blood ; Gliclazide/*therapeutic use ; Platelet Aggregation/*drug effects ; Sulfonylurea Compounds/*therapeutic use; Clinical Trials as Topic ; Diabetic Angiopathies/blood ; Diabetic Angiopathies/prevention & control ; Double-Blind Method ; Glyburide/therapeutic use ; Humans ; Random Allocation
    • Abstract:
      Previous studies have suggested that the sulphonylurea hypoglycaemic agent gliclazide has specific effects in inhibiting platelet aggregation, and other haemorrheological effects that could be beneficial in preventing diabetic microangiopathy. A double-blind trial of the effect of gliclazide on platelet aggregatory responses was performed in 51 diabetic patients. Insulin- and non-insulin-treated diabetics were assessed during an initial 12-month placebo period, and in a subsequent 24-month active period after randomisation into placebo and gliclazide groups in insulin-treated patients or to glibenclamide and gliclazide groups in non-insulin-treated patients. Platelet-rich plasma was obtained from patients at intervals of at least 6 months during the trial. Circulating platelet aggregates were estimated, platelet aggregation was studied in response to three concentrations of adrenaline, ADP and collagen and thromboxane B2 produced by platelets exposed to collagen was measured. No significant effect of gliclazide was demonstrated on any parameter of platelet function evaluated.
    • Accession Number:
      0 (Sulfonylurea Compounds)
      G4PX8C4HKV (Gliclazide)
      SX6K58TVWC (Glyburide)
    • Publication Date:
      Date Created: 19880107 Date Completed: 19880406 Latest Revision: 20190908
    • Publication Date:
      20221208
    • Accession Number:
      10.1016/s0168-8227(88)80001-9
    • Accession Number:
      3125029